Buy & Sell CVS Health Corp (CVS) – CVS Health Corp Price Today
Aura AI Summary
Key Stats
- $133.54BMarket Cap
- HealthSector
- -8.78%3M Drawdown
- $200.08BEnterprise Value
- 2.54%Dividend Yield
- 5% Buy | 95% SellTrading Activity
- 81 daysTypical Hold Time
CVS Health Corp (CVS) is currently valued at a market capitalization of $133.54B, with an enterprise value of $200.08B. Over the past 52 weeks, CVS Health Corp has traded between a low of $58.75 and a high of $105.03, highlighting its annual price range. Over the past three months, CVS Health Corp has recorded a drawdown of -8.78%, reflecting recent price volatility. CVS Health Corp offers a dividend yield of 2.54%, with the most recent dividend of $0.67 paid on 23 Apr 26. On average, investors hold CVS Health Corp for approximately 81 days, indicating typical investor behavior on the platform.
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Most Recent News
Complex small molecules reshape drug R&D, demanding integrated discovery to manufacturing solutions.
WuXi AppTec highlights how the increasing structural complexity of small molecules, such as targeted protein degraders and covalent inhibitors, is transforming drug research and development. These new molecules require advanced, integrated approaches...

Axsome starts Phase 3 trial of solriamfetol for ADHD in adolescents, aiming to improve treatment options.
Axsome Therapeutics has initiated the FOCUS-3 Phase 3 clinical trial to evaluate solriamfetol as a treatment for adolescents aged 12 to under 18 with ADHD. This randomized, double-blind, placebo-controlled study will enroll about 468 patients to asse...

SoundHound AI's COO sells 65,000 shares, signaling insider stock movement.
SoundHound AI's Chief Operating Officer has sold 65,000 shares of the company's stock. This insider sale could indicate personal financial decisions or a strategic move related to the company's outlook. Investors often watch such transactions closely...
